title: [The pharmacology of the new combined anti-arrhythmia preparation metatsizin].
abstract: The combined antiarrhythmic effect of ethmosin and ethacisin in various dose ratios was studied in conscious dogs with two-stage ligation of the coronary artery (after Harris). A 6:1 ratio was found to be optimal for manifestation of the antiarrhythmic effect. In such a ratio of the doses the antiarrhythmic effect of a combination of ethmosin and ethacisin is essentially higher than the activity of each component. On the grounds of these data a combined antiarrhythmic drug methacisin was developed. It possesses a broad spectrum of antiarrhythmic activity. The drug is effective on models of arrhythmias specific of class I, III, and IV antiarrhythmics. Metacisin does not change hemodynamics and activity of the heart. Study of metacisin pharmacokinetics showed that it possesses bioavailability twice that of ethmosin tablets taken separately and four times that of ethasicin.
authors.affiliation: Laboratory of Blood Circulation Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
authors.forename: N V
authors.initials: NV
authors.lastname: Kaverina
authors.forename: G G
authors.initials: GG
authors.lastname: Chichkanov
authors.forename: E M
authors.initials: EM
authors.lastname: Bugriĭ
authors.forename: M B
authors.initials: MB
authors.lastname: Vititnova
authors.forename: E A
authors.initials: EA
authors.lastname: Tolmacheva
authors.forename: A I
authors.initials: AI
authors.lastname: Turilova
authors.forename: S A
authors.initials: SA
authors.lastname: Kryzhanovskiĭ
authors.forename: V V
authors.initials: VV
authors.lastname: Lyskovtsev
authors.forename: A P
authors.initials: AP
authors.lastname: Rodionov
authors.forename: V L
authors.initials: VL
authors.lastname: Beloborodov
mesh_terms: D000157:Aconitine; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy; D017609:Barium Compounds; D002712:Chlorides; D004285:Dogs; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004562:Electrocardiography / Q000187:drug effects; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D016293:Moricizine / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D010640:Phenothiazines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011189:Potassium Chloride; D011817:Rabbits; D051381:Rats; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D017609:Barium Compounds; D002712:Chlorides; D004338:Drug Combinations; D010640:Phenothiazines; C024986:barium chloride; D016293:Moricizine; D011189:Potassium Chloride; C046818:ethacizine; D000157:Aconitine
vernacular_title: K farmakologii novogo kombinirovannogo antiaritmicheskogo preparata metatsizina.